Core Insights - The Oncology Institute, Inc. (TOI) reported a strong start to 2025, with expectations for sustained cash flow positivity and profitability in the second half of the year, driven by operational efficiencies and strategic market expansion [4][5][6] - The company anticipates adding approximately $50 million in new revenue from new capitation contracts projected for the first half of 2025, with a potential increase of 100,000 lives in the second half of the year [4][6] Recent Operational Highlights - TOI achieved consolidated revenue of $104.4 million in Q1 2025, a 10.3% increase from $94.7 million in Q1 2024 [8] - The retail pharmacy and dispensary segment generated $49.3 million in revenue, growing over 20% year-over-year [6][9] - Fee-for-service revenue grew by 9% in Q1 2025 compared to Q4 2024, reflecting investments in referral management and call center expansion [6] Financial Performance - Gross profit for Q1 2025 was $17.2 million, a 44.1% increase from the prior year quarter [10] - The net loss for Q1 2025 was $19.6 million, slightly improved from a net loss of $19.9 million in Q1 2024 [12] - Adjusted EBITDA improved to $(5.1) million in Q1 2025 from $(10.9) million in Q1 2024 [12][20] Guidance for Fiscal Year 2025 - TOI expects full-year revenue to be between $460 million and $480 million, with gross profit projected between $73 million and $82 million [7] - The company anticipates Adjusted EBITDA to range from $(8) million to $(17) million for the year [7] Key Business Metrics - As of March 31, 2025, TOI operated 81 clinics across 18 markets, serving approximately 1.9 million lives under value-based contracts [32] - Cash and cash equivalents stood at $39.7 million as of March 31, 2025, down from $49.7 million at the end of 2024 [33]

Company Overview - The Oncology Institute, Inc. (TOI) is one of the largest value-based oncology groups in the United States, founded in 2007 [3] - TOI provides specialized, evidence-based cancer care to over 1.8 million patients, including clinical trials and transfusions, with over 120 employed clinicians and more than 700 staff across 70 clinic locations [3] Leadership Change - Dr. Jeffrey Langsam has been appointed as the Chief Clinical Officer (CCO) of TOI, effective May 13, 2025 [1] - Dr. Langsam previously held significant roles at Cigna Healthcare and Aetna, bringing extensive experience in oncology and specialty pharmacy to TOI [1][2] Strategic Focus - The appointment of Dr. Langsam is expected to enhance TOI's therapeutic decision-making model and support the growth of its Managed Services Organization (MSO) model [2] - The company is experiencing an acceleration in new value-based partnerships and risk-based contracts, positioning it for continued growth in clinical offerings [2]

Company Overview - Topicus.com Inc. is a leading pan-European provider of vertical market software and platforms, serving clients in both public and private sectors [3] - The company focuses on acquiring, building, and managing software companies that deliver specialized, mission-critical, and high-impact software solutions tailored to customer needs [3] Board of Directors - At the annual general meeting held on May 13, 2025, all five director nominees were elected to the board: John Billowits, Alex Macdonald, Lori O'Neill, Donna Parr, and Robin van Poelje [1] - Jane Holden did not stand for re-election, and the company expressed gratitude for her contributions as a board member [2]

Core Insights - The Oncology Institute, Inc. (TOI) is one of the largest value-based oncology groups in the United States, focusing on specialized cancer care [1][2] - TOI will participate in B. Riley's 25th Annual Institutional Investor Conference on May 21, 2025, with key executives attending [1] Company Overview - Founded in 2007, TOI provides value-based cancer care to over 1.8 million patients, including services like clinical trials and transfusions [2] - The organization employs over 120 clinicians and has more than 700 staff across 70 clinic locations, aiming to improve oncology care [2]

Core Insights - The Oncology Institute, Inc. (TOI) has been selected to present an abstract at the ASCO Annual Meeting, highlighting the cost savings and reduced hospitalizations associated with its High-Value Cancer Care (HVCC) model [1][2] - The HVCC model has demonstrated over 50% reductions in Emergency Department utilization and hospitalizations, along with cost savings exceeding $12,000 per patient enrolled [2][5] Company Overview - Founded in 2007, TOI specializes in value-based cancer care, serving over 1.8 million patients with a team of over 120 clinicians and more than 700 staff across 70 clinic locations [4] - TOI's approach includes evidence-based cancer care, clinical trials, and transfusions, aiming to improve oncology care in community settings [4] Clinical Outcomes - Recent data indicates a 53% reduction in Emergency Department use, a 68% decrease in hospitalizations, and a 75% lower odds of death in acute care facilities for patients enrolled in the HVCC model [5] - The total cost of care is lowered by $12,000 per enrolled patient, further validating the effectiveness of TOI's care model [5]

TORONTO, May 07, 2025 (GLOBE NEWSWIRE) -- Topicus.com Inc. (TSXV:TOI) in a joint release with Constellation Software Inc. (TSX:CSU) today announced financial results for Topicus.com Inc. (“Topicus” or the “Company”) for the first quarter ended March 31, 2025. Please note that all amounts referred to in this press release are in Euros unless otherwise stated. The following press release should be read in conjunction with the Company’s Unaudited Condensed Consolidated Interim Financial Statements for the thre ...

TORONTO, May 01, 2025 (GLOBE NEWSWIRE) -- Topicus.com Inc. (TSXV:TOI) (the “Company”) announced today that the release of its first quarter results will be rescheduled. The Company will defer the release of its results from the originally planned date of May 2, 2025 in order to allow the Company to finalize its analysis and accounting for certain Q1 2025 complex transactions impacting the condensed consolidated interim financial statements. The Company’s quarterly results are expected to be disseminated via ...

Core Viewpoint - The Oncology Institute, Inc. (TOI) will announce its first quarter 2025 financial results on May 14, 2025, after market close, followed by a conference call at 5:00 p.m. Eastern Time [1]. Group 1: Financial Results Announcement - TOI is set to release its Q1 2025 financial results on May 14, 2025, after the market closes [1]. - A conference call will take place on the same day at 5:00 p.m. Eastern Time to discuss the results [1]. Group 2: Conference Call Access - The conference call can be accessed by dialing 1-877-407-0789 for domestic callers and 1-201-689-8562 for international callers [2]. - A replay of the call will be available two hours after it concludes, accessible at 1-844-512-2921 for domestic and 1-412-317-6671 for international callers, with a passcode of 13752832 [2]. - The replay will be available until May 21, 2025 [2]. Group 3: Webcast Information - Interested parties can also listen to a simultaneous webcast of the conference call via the Investor Relations section of TOI's website [3]. Group 4: Company Overview - Founded in 2007, TOI specializes in value-based cancer care, serving over 1.8 million patients with advanced oncology services [4]. - The company employs over 120 clinicians and has more than 700 staff across over 70 clinic locations [4].

Core Insights - The Oncology Institute, Inc. (TOI) is expanding its strategic partnership with Helios Clinical Research to enhance community oncology care through integrated clinical research [1][2] - The partnership aims to streamline study activation, accelerate enrollment, and reduce operational burdens, allowing TOI to scale its research infrastructure while maintaining a focus on patient care [2] - TOI serves over 1.8 million patients and employs over 120 clinicians across more than 70 clinic locations, emphasizing its commitment to value-based cancer care [3] Strategic Benefits of the Partnership - Patients will have increased access to advanced therapies through clinical trials supported by Helios' centralized operations [5] - Sponsors will benefit from improved trial performance due to streamlined startup processes and optimized patient matching [5] - The partnership aims to enhance equity in oncology research by enrolling diverse and underrepresented patient populations [5]

Group 1 - Topicus.com Inc. plans to release its first quarter results on May 2, 2025 [1] - The quarterly results will be available via press release and on the Company's website and SEDAR website after market close on May 2, 2025 [1] - Topicus' subordinate voting shares are listed on the Toronto Venture Stock Exchange under the symbol "TOI" [2] Group 2 - Topicus focuses on acquiring, managing, and building vertical market software businesses [2]